Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.67 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.67 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | RAB9A | P51151 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.63 |
| ▸ | F10 | P00742 | 2/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918623 | 0.87 | PTPN7 (0.77) | PTPN7PTPN12PTPN22NPC1RAB9A | |
| SCHEMBL4253115 | 0.83 | PRSS12 (0.67) | PTPN7PTPN12PTPN22LRRK2NPC1 | |
| SCHEMBL4249984 | 0.82 | PTPN7 (0.63) | PTPN7PTPN12PTPN22NPC1RAB9A | |
| SCHEMBL4250099 | 0.79 | MAPT (0.70) | PTPN7PTPN12PTPN22NPC1RAB9A | |
| SCHEMBL30370064 | 0.78 | LRRK2 (1.00) | LRRK2NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16562249 | 0.77 | MAPT (0.76) | NPC1RAB9ASMN1; SMN2MAPTF10 | |
| SCHEMBL16553806 | 0.76 | MAPT (0.66) | NPC1RAB9ASMN1; SMN2MAPTPRSS12 | |
| SCHEMBL15347245 | 0.74 | TLR3 (0.56) | NPC1RAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL2242799 | 0.74 | NPC1 (0.70) | LRRK2NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3787846 | 0.74 | DYRK1A (0.76) | LRRK2NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | PTPN7 4048/4885PTPN12 3929/4885PTPN22 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.